Tomorrows, a global health technology company that connects patients and physicians with pre-approval treatments, today published a new data report, entitled Searching for solutions: How physicians ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

Tony Newberne is a high-risk multiple myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several ...

Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month ...

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

Cancer, a disease long though incurable, has been not only treated, but also through research and trials. Healthcare professionals have also found ways that help people be cancer-free. However, recent ...

Developing new biomarker assays is highly specialised work. It requires careful screening of antibody pairs, sensitivity and specificity testing, and performance validation across different sample ...

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, shares how the company is driving more inclusive enrollment by engaging diverse communities, developing culturally ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

Findings from the Melanoma Group at the Spanish National Cancer Research Centre (CNIO) led to the creation of the Spanish ...